

Eric Hahnen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2946855/publications.pdf>

Version: 2024-02-01

68
papers

4,807
citations

136950

32
h-index

106344

65
g-index

75
all docs

75
docs citations

75
times ranked

6725
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Breast Care</i> , 2022, 17, 199-207.	1.4	12
2	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
3	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	2.8	12
4	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	1.6	90
5	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
6	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
7	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
8	Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 565-570.	6.3	17
9	Effect of HIPEC according to HRD/ <i>BRCA</i> wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. <i>International Journal of Cancer</i> , 2022, 151, 1394-1404.	5.1	15
10	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	8.2	19
11	Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. <i>Cancers</i> , 2022, 14, 3363.	3.7	2
12	Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3292.	3.7	11
13	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
14	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
15	Evaluation of the association of heterozygous germline variants in <i>NTHL1</i> with breast cancer predisposition: an international multi-center study of 47,180 subjects. <i>Npj Breast Cancer</i> , 2021, 7, 52.	5.2	7
16	Pathological complete response rate and survival in patients with <i>BRCA</i> -associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).. <i>Journal of Clinical Oncology</i> , 2021, 39, 579-579.	1.6	3
17	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). <i>Journal of Personalized Medicine</i> , 2021, 11, 511.	2.5	59
18	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
20	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
21	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	10.7	248
22	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
23	Ovarian Cancerâ€™Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	7.0	9
24	Performance of In Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer. <i>Cancers</i> , 2021, 13, 118.	3.7	4
25	Performance of Breast Cancer Polygenic Risk Scores in 760 Female <i>CHEK2</i> Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 893-899.	6.3	21
26	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
27	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
28	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	5.1	32
29	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
30	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	1.6	270
31	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
32	Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	5.2	5
33	Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i> : results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107353.	3.2	3
34	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
35	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 744.	7.1	42
36	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48

#	ARTICLE	IF	CITATIONS
37	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
38	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. <i>BMC Cancer</i> , 2019, 19, 787.	2.6	10
39	Biallelic germline <i>BRCA1</i> mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e863.	1.2	22
40	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	2.5	102
41	Germline loss-of-function variants in the <i>BARD1</i> gene are associated with early-onset familial breast cancer but not ovarian cancer. <i>Breast Cancer Research</i> , 2019, 21, 55.	5.0	44
42	Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. <i>Breast Journal</i> , 2019, 25, 455-460.	1.0	35
43	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	3.2	34
44	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
45	The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1761-1763.	5.1	2
46	Gene panel testing of 5589 <i>BRCA1/2</i> negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancer Medicine</i> , 2018, 7, 1349-1358.	2.8	126
47	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
48	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. <i>Genetics in Medicine</i> , 2018, 20, 452-457.	2.4	59
49	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. <i>Human Mutation</i> , 2018, 39, 394-405.	2.5	24
50	Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. <i>Oncology Letters</i> , 2018, 15, 4093-4096.	1.8	10
51	Diagnosis of Li-Fraumeni Syndrome: Differentiating <i>TP53</i> germline mutations from clonal hematopoiesis. <i>Human Mutation</i> , 2018, 39, 2040-2046.	2.5	20
52	Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics. <i>BMC Medical Genomics</i> , 2018, 11, 35.	1.5	78
53	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 7.	5.0	78
54	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018, 18, 265.	2.6	84

#	ARTICLE	IF	CITATIONS
55	Germline Mutations in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 15-19.	1.4	59
56	Association Between Loss-of-Function Mutations Within the <i>FANCM</i> Gene and Early-Onset Familial Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1245.	7.1	74
57	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	7.1	300
58	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
59	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	2.5	105
60	<i>BRCA</i> -like classification in ovarian cancer: Results from the AGO-TR1-trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5546-5546.	1.6	3
61	Prevalence of <i>BRCA1/2</i> germline mutations in 21â€¦401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 465-471.	3.2	179
62	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
63	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	5.0	42
64	Incidence of germline mutations in risk genes including <i>BRCA1/2</i> in consecutive ovarian cancer (OC) patients (AGO TR-1).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5538-5538.	1.6	2
65	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
66	RAD51Cdeletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. <i>Breast Cancer Research</i> , 2013, 15, R120.	5.0	28
67	Drug discovery for spinal muscular atrophy. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 437-451.	5.0	4
68	In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2006, 98, 193-202.	3.9	140